{'fraction_non_alphanumeric': 0.04426002766251729, 'fraction_numerical': 0.04149377593360996, 'mean_word_length': 4.838709677419355, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preinduction Cervical Softening with Endocervical Pge2 Gel: A multi‐center trial

In a prospective, randomized trial, a single dose of PGE2 gel, 0.5 mg (2.5 ml), was given to 416 low Bishop Score patients 12 h prior to indicated oxytocin induction and compared with 404 non‐gel controls. Successful initial induction was achieved in 83% of the treated and 58% of the non‐treated subjects. In addition the induction—delivery interval was shortened (median times 9.0 h vs. 11.3 h) and fewer cesarean sections were performed (16% vs. 21%) in the PGE2 gel series. The endocervical administration of PGE2 was well tolerated and, provided care is taken to avoid excess extra‐amniotic placement, systemic PGE2 effects are minimal.